|
Astrocytic
Tumors |
|
|
|
|
Sathornsumetee S, Cao Y, Marcello JE, Herndon JE
2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ,
Rich JN
Tumor angiogenic and hypoxic profiles predict radiographic response and
survival in malignant astrocytoma patients treated with bevacizumab and
irinotecan
J
Clin Oncol. 2008 Jan 10;26(2):271-8
 Abstract |
DBLinks | BL 7:6
|
|
|
Glioblastoma |
|
|
|
|
Chamberlain MC
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma
J Clin Oncol. 2008 Feb 20;26(6):1012-1013
Abstract |
 Full Text |
 Reprint |
DBLinks | BL 7:5
|
|
|
Chowdhary S, Wong ET
Bevacizumab combined with irinotecan for recurrent glioblastoma
multiforme-improvement over available therapy?
Nat Clin Pract Neurol. 2008 Jan 22. [Epub ahead of print]
Abstract |
DBLinks | BL 7:3
|
|
|
J. Kirkpatrick, A. Desjardins, J. J. Vredenburgh, J. A. Quinn, J. N.
Rich, S. Sathornsumetee, S. Gururangan, A. H. Friedman, H. S. Friedman, D.
A. Reardon
Combination of bevacizumab, a monoclonal antibody to vascular endothelial
growth factor (VEGF), and temozolomide: Study of cases
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings
(Post-Meeting Edition).
Vol 24, No 18S (June 20 Supplement), 2006: 11522
|
|
|
James J. Vredenburgh,
Annick Desjardins, David A. Reardon, Henry
S. Friedman
In Reply
Journal of Clinical Oncology, Vol 26, No 6 (February 20),
2008: pp. 1013. DOI:
10.1200/JCO.2007.15.1746
Abstract |
Full Text |
Reprint |
DBLinks | BL 7:5
|
|
|
Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham
C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T.
Phase II Pilot Study of Bevacizumab in Combination With Temozolomide and
Regional Radiation Therapy for Up-Front Treatment of Patients With Newly
Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and
Tolerability
Int
J Radiat Oncol Biol Phys. 2008 Mar 20; [Epub ahead of print]
Abstract |
DBLinks | BL 7:7
|
|
|
Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich
JN,
Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD,
Friedman AH, Friedman HS.
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
J
Clin Oncol. 2007 Oct 20;25(30):4722-9.
Abstract |
Full
Text |
Reprint
|
DBLinks
|
|
|
Gliomas |
|
|
|
|
Norden AD, Young GS, Setayesh K, Muzikansky A,
Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen
PY
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and
patterns of recurrence
Neurology. 2008 Mar 4;70(10):779-87
Abstract |
DBLinks | BL 7:6
|
|
|
J. J. Vredenburgh, A. Desjardins, J. E. Herndon, J. Quinn, J. Rich, S.
Sathornsumetee, H. S. Friedman, D. Reardon, S. Gururangan, A. Friedman
Bevacizumab, a monoclonal antibody to vascular endothelial growth factor
(VEGF),
and irinotecan for treatment of malignant gliomas
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings
(Post-Meeting Edition).
Vol 24, No 18S (June 20 Supplement), 2006: 1506
|
|
|
|
